Search - tctmd.com

Displaying 1 - 20 of 710

Sort: Relevancy | Date

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

News Conference News AHA 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

November 13, 2025

Beta-blockers Not Helpful After MI in Patients With Preserved EF

News Conference News AHA 2025

Beta-blockers Not Helpful After MI in Patients With Preserved EF

Yael L. Maxwell

November 12, 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

News Conference News AHA 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

November 09, 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

News Conference News AHA 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

November 08, 2025

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure ANDES

News Conference News TCT 2025

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES

Yael L. Maxwell

November 04, 2025

Evolocumab Wins for Primary Prevention in VESALIUS-CV

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

October 03, 2025

CVD Still the Leading Cause of Death and Disease Globally

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

News Daily News

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

Michael O'Riordan

September 23, 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

News Conference News ESC 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

September 05, 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

September 01, 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

TCTMD’s Top 10 Most Popular Stories for July 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2025

July 31, 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

News Conference News SCCT 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

Yael L. Maxwell

July 21, 2025

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

News Daily News

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

July 16, 2025

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

News Daily News

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Yael L. Maxwell

June 09, 2025

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

News Conference News EuroPCR 2025

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Yael L. Maxwell

June 02, 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

News Conference News EuroPCR 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

May 30, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.